[18F]FDG-PET/CT’s change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial
Authors
John B.A.G. Haanen (ORCID: https://orcid.org/0000-0001-5884-7704)
[18F]FDG-PET/CT’s change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial
John B.A.G. Haanen, Maurits Wondergem, Wouter V. Vogel, Laura A. Smit et al.
Citations
1 citations
Journal
European Journal of Nuclear Medicine and Molecular Imaging
Topics
Nonmelanoma Skin Cancer Studies
Field-Weighted Citation Impact (FWCI)
1.35
article
[18F]FDG-PET/CT’s change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial
John B.A.G. Haanen, Maurits Wondergem, Wouter V. Vogel, Laura A. Smit, Arash Navran, Charlotte L. Zuur, Winan J. van Houdt, Jan Paul de Boer, Sabine E. Breukers, Lot A. Devriese, Remco de Bree, Robert D. Crommelin
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
European Journal of Nuclear Medicine and Molecular ImagingVol. 53(4)
Institutions
Dutch Cancer Society (NL), Leiden University Medical Center (NL), The Netherlands Cancer Institute (NL), University Medical Center Utrecht (NL), Oncode Institute (NL), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NL)